GRACEcast

By Howard (Jack) West, MD

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Edu... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.

GRACEcast episodes:

July 20, 2014 How is the Heng Criteria Applied to Kidney Cancer Patients?
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
...more
5min
July 20, 2014 How is the Heng Criteria Applied to Kidney Cancer Patients?
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
...more
5min
July 17, 2014 Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
...more
8min
July 17, 2014 Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
...more
8min
July 15, 2014 What is PD1 and PDL1 in Kidney Cancer?
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.
...more
4min
July 15, 2014 What is PD1 and PDL1 in Kidney Cancer?
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.
...more
4min
July 13, 2014 Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
...more
8min
July 13, 2014 Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
...more
8min
July 10, 2014 No Clear Answer for Non-Clear Cell Kidney Cancer
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.
...more
6min
July 10, 2014 No Clear Answer for Non-Clear Cell Kidney Cancer
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.
...more
6min

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.